Targeted treatment can significantly reduce relapse in children with AML leukemia
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with ...
Dec 8, 2013
0
0